+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

End Stage Renal Disease Market Research Report by Treatment (Dialysis and Transplantation), Diagnosis, End-User, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 157 Pages
  • July 2022
  • Region: United States
  • 360iResearch™
  • ID: 5337853
UP TO OFF until Dec 31st 2022
The United States End Stage Renal Disease Market size was estimated at USD 7,173.99 million in 2021, USD 8,638.02 million in 2022, and is projected to grow at a CAGR 16.63% to reach USD 18,063.62 million by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the End Stage Renal Disease to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Treatment, the market was studied across Dialysis and Transplantation. The Dialysis is further studied across Hemodialysis, Peritoneal Dialysis, and Wearable Artificial Kidney.
  • Based on Diagnosis, the market was studied across Blood tests, Imaging tests, Kidney sample removal for testing, and Urine tests.
  • Based on End-User, the market was studied across Dialysis Centres, Hospital & Clinics, and Research and Academic Institutes.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for End Stage Renal Disease market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the End Stage Renal Disease Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States End Stage Renal Disease Market, including Abbott, Amgen Inc., Asahi Kasei Medical Co., Ltd., AstraZeneca, B. Braun Melsungen AG, Baxter International, Inc., BD, Bristol-Myers Squibb Company, Cantel Medical, Davita Healthcare Partners Inc., F. Hoffmann-La Roche Ltd, Fresenius Medical Care AG & Co. KGaA, GlaxoSmithKline PLC, JMS Co. Ltd., Keryx Biopharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd, Medtronic, Nikkiso Co., Ltd., Novartis AG, Pfizer Inc., Sanofi SA, and Teva Pharmaceutical Industries Ltd.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the United States End Stage Renal Disease Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States End Stage Renal Disease Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States End Stage Renal Disease Market?
4. What is the competitive strategic window for opportunities in the United States End Stage Renal Disease Market?
5. What are the technology trends and regulatory frameworks in the United States End Stage Renal Disease Market?
6. What is the market share of the leading vendors in the United States End Stage Renal Disease Market?
7. What modes and strategic moves are considered suitable for entering the United States End Stage Renal Disease Market?
Frequently Asked Questions about the U.S. End Stage Renal Disease Market

What is the estimated value of the U.S. End Stage Renal Disease Market?

The U.S. End Stage Renal Disease Market was estimated to be valued at $7173.99 Million in 2021.

What is the growth rate of the U.S. End Stage Renal Disease Market?

The growth rate of the U.S. End Stage Renal Disease Market is 16.6%, with an estimated value of $18063.62 Million by 2027.

What is the forecasted size of the U.S. End Stage Renal Disease Market?

The U.S. End Stage Renal Disease Market is estimated to be worth $18063.62 Million by 2027.

Who are the key companies in the U.S. End Stage Renal Disease Market?

Key companies in the U.S. End Stage Renal Disease Market include Abbott, Amgen Inc., Asahi Kasei Medical Co., Ltd., AstraZeneca, B. Braun Melsungen AG, Baxter International, Inc., BD, Bristol and Cantel Medical.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. End Stage Renal Disease Market, by Treatment
6.1. Introduction
6.2. Dialysis
6.2.1. Hemodialysis
6.2.2. Peritoneal Dialysis
6.2.3. Wearable Artificial Kidney
6.3. Transplantation
7. End Stage Renal Disease Market, by Diagnosis
7.1. Introduction
7.2. Blood tests
7.3. Imaging tests
7.4. Kidney sample removal for testing
7.5. Urine tests
8. End Stage Renal Disease Market, by End-User
8.1. Introduction
8.2. Dialysis Centres
8.3. Hospital & Clinics
8.4. Research and Academic Institutes
9. California End Stage Renal Disease Market10. Florida End Stage Renal Disease Market11. Illinois End Stage Renal Disease Market12. New York End Stage Renal Disease Market13. Ohio End Stage Renal Disease Market14. Pennsylvania End Stage Renal Disease Market15. Texas End Stage Renal Disease Market
16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion
17. Company Usability Profiles
17.1. Abbott
17.2. Amgen Inc.
17.3. Asahi Kasei Medical Co., Ltd.
17.4. AstraZeneca
17.5. B. Braun Melsungen AG
17.6. Baxter International, Inc.
17.7. BD
17.8. Bristol-Myers Squibb Company
17.9. Cantel Medical
17.10. Davita Healthcare Partners Inc.
17.11. F. Hoffmann-La Roche Ltd
17.12. Fresenius Medical Care AG & Co. KGaA
17.13. GlaxoSmithKline PLC
17.14. JMS Co. Ltd.
17.15. Keryx Biopharmaceuticals, Inc.
17.16. Kissei Pharmaceutical Co., Ltd
17.17. Medtronic
17.18. Nikkiso Co., Ltd.
17.19. Novartis AG
17.20. Pfizer Inc.
17.21. Sanofi SA
17.22. Teva Pharmaceutical Industries Ltd
18. Appendix
18.1. Discussion Guide
18.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES END STAGE RENAL DISEASE MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, 2021 VS 2027 (USD MILLION)
FIGURE 3. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 4. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 5. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY STATE, 2027
FIGURE 7. UNITED STATES END STAGE RENAL DISEASE MARKET DYNAMICS
FIGURE 8. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2021 VS 2027 (%)
FIGURE 9. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2021 VS 2027 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2027
FIGURE 11. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, 2019-2027 (USD MILLION)
FIGURE 12. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 13. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2019-2027 (USD MILLION)
FIGURE 14. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 15. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2019-2027 (USD MILLION)
FIGURE 16. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 17. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY WEARABLE ARTIFICIAL KIDNEY, 2019-2027 (USD MILLION)
FIGURE 18. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY WEARABLE ARTIFICIAL KIDNEY, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 19. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANTATION, 2019-2027 (USD MILLION)
FIGURE 20. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANTATION, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 21. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2021 VS 2027 (%)
FIGURE 22. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2021 VS 2027 (USD MILLION)
FIGURE 23. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2027
FIGURE 24. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY BLOOD TESTS, 2019-2027 (USD MILLION)
FIGURE 25. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY BLOOD TESTS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 26. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY IMAGING TESTS, 2019-2027 (USD MILLION)
FIGURE 27. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY IMAGING TESTS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 28. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY KIDNEY SAMPLE REMOVAL FOR TESTING, 2019-2027 (USD MILLION)
FIGURE 29. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY KIDNEY SAMPLE REMOVAL FOR TESTING, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 30. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY URINE TESTS, 2019-2027 (USD MILLION)
FIGURE 31. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY URINE TESTS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 32. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2021 VS 2027 (%)
FIGURE 33. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2021 VS 2027 (USD MILLION)
FIGURE 34. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2027
FIGURE 35. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTRES, 2019-2027 (USD MILLION)
FIGURE 36. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTRES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 37. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITAL & CLINICS, 2019-2027 (USD MILLION)
FIGURE 38. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITAL & CLINICS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 39. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, 2019-2027 (USD MILLION)
FIGURE 40. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 41. CALIFORNIA END STAGE RENAL DISEASE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 42. FLORIDA END STAGE RENAL DISEASE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 43. ILLINOIS END STAGE RENAL DISEASE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 44. NEW YORK END STAGE RENAL DISEASE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 45. OHIO END STAGE RENAL DISEASE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 46. PENNSYLVANIA END STAGE RENAL DISEASE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 47. TEXAS END STAGE RENAL DISEASE MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 48. UNITED STATES END STAGE RENAL DISEASE MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 49. UNITED STATES END STAGE RENAL DISEASE MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 50. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES END STAGE RENAL DISEASE MARKET, BY TYPE
List of Tables
TABLE 1. UNITED STATES END STAGE RENAL DISEASE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 4. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY STATE, 2019-2027 (USD MILLION)
TABLE 5. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2019-2027 (USD MILLION)
TABLE 6. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS, BY STATE, 2019-2027 (USD MILLION)
TABLE 7. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY STATE, 2019-2027 (USD MILLION)
TABLE 8. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY STATE, 2019-2027 (USD MILLION)
TABLE 9. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY WEARABLE ARTIFICIAL KIDNEY, BY STATE, 2019-2027 (USD MILLION)
TABLE 10. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANTATION, BY STATE, 2019-2027 (USD MILLION)
TABLE 11. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2019-2027 (USD MILLION)
TABLE 12. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY BLOOD TESTS, BY STATE, 2019-2027 (USD MILLION)
TABLE 13. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY IMAGING TESTS, BY STATE, 2019-2027 (USD MILLION)
TABLE 14. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY KIDNEY SAMPLE REMOVAL FOR TESTING, BY STATE, 2019-2027 (USD MILLION)
TABLE 15. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY URINE TESTS, BY STATE, 2019-2027 (USD MILLION)
TABLE 16. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2019-2027 (USD MILLION)
TABLE 17. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTRES, BY STATE, 2019-2027 (USD MILLION)
TABLE 18. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITAL & CLINICS, BY STATE, 2019-2027 (USD MILLION)
TABLE 19. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, BY STATE, 2019-2027 (USD MILLION)
TABLE 20. CALIFORNIA END STAGE RENAL DISEASE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 21. CALIFORNIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2019-2027 (USD MILLION)
TABLE 22. CALIFORNIA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2019-2027 (USD MILLION)
TABLE 23. CALIFORNIA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2019-2027 (USD MILLION)
TABLE 24. FLORIDA END STAGE RENAL DISEASE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 25. FLORIDA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2019-2027 (USD MILLION)
TABLE 26. FLORIDA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2019-2027 (USD MILLION)
TABLE 27. FLORIDA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2019-2027 (USD MILLION)
TABLE 28. ILLINOIS END STAGE RENAL DISEASE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 29. ILLINOIS END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2019-2027 (USD MILLION)
TABLE 30. ILLINOIS END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2019-2027 (USD MILLION)
TABLE 31. ILLINOIS END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2019-2027 (USD MILLION)
TABLE 32. NEW YORK END STAGE RENAL DISEASE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 33. NEW YORK END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2019-2027 (USD MILLION)
TABLE 34. NEW YORK END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2019-2027 (USD MILLION)
TABLE 35. NEW YORK END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2019-2027 (USD MILLION)
TABLE 36. OHIO END STAGE RENAL DISEASE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 37. OHIO END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2019-2027 (USD MILLION)
TABLE 38. OHIO END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2019-2027 (USD MILLION)
TABLE 39. OHIO END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2019-2027 (USD MILLION)
TABLE 40. PENNSYLVANIA END STAGE RENAL DISEASE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 41. PENNSYLVANIA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2019-2027 (USD MILLION)
TABLE 42. PENNSYLVANIA END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2019-2027 (USD MILLION)
TABLE 43. PENNSYLVANIA END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2019-2027 (USD MILLION)
TABLE 44. TEXAS END STAGE RENAL DISEASE MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 45. TEXAS END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2019-2027 (USD MILLION)
TABLE 46. TEXAS END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2019-2027 (USD MILLION)
TABLE 47. TEXAS END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2019-2027 (USD MILLION)
TABLE 48. UNITED STATES END STAGE RENAL DISEASE MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 49. UNITED STATES END STAGE RENAL DISEASE MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 50. UNITED STATES END STAGE RENAL DISEASE MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 51. UNITED STATES END STAGE RENAL DISEASE MARKET RANKING
TABLE 52. UNITED STATES END STAGE RENAL DISEASE MARKET SHARE, BY KEY PLAYER, 2021
TABLE 53. UNITED STATES END STAGE RENAL DISEASE MARKET MERGER & ACQUISITION
TABLE 54. UNITED STATES END STAGE RENAL DISEASE MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 55. UNITED STATES END STAGE RENAL DISEASE MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 56. UNITED STATES END STAGE RENAL DISEASE MARKET INVESTMENT & FUNDING
TABLE 57. UNITED STATES END STAGE RENAL DISEASE MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 58. UNITED STATES END STAGE RENAL DISEASE MARKET: LICENSE & PRICING

Companies Mentioned

  • Abbott
  • Amgen Inc.
  • Asahi Kasei Medical Co., Ltd.
  • AstraZeneca
  • B. Braun Melsungen AG
  • Baxter International, Inc.
  • BD
  • Bristol-Myers Squibb Company
  • Cantel Medical
  • Davita Healthcare Partners Inc.
  • F. Hoffmann-La Roche Ltd
  • Fresenius Medical Care AG & Co. KGaA
  • GlaxoSmithKline PLC
  • JMS Co. Ltd.
  • Keryx Biopharmaceuticals, Inc.
  • Kissei Pharmaceutical Co., Ltd
  • Medtronic
  • Nikkiso Co., Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd

Methodology

Loading
LOADING...